他莫昔芬在某些患者中出现治疗应答降低的风险
摘要
欧洲药品管理局（EMA）人用药品委员会药物警戒工作组（PhVWP）在2010年9月份召开的全体会议中讨论了他莫昔芬在某些患者中出现治疗应答降低的风险。
出处
《中国执业药师》
CAS
2011年第7期20-21,共2页
China Licensed Pharmacist
参考文献14
-
1Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen [J]. J Am Med Assoc, 2009, 302(13): 1429-1436.
-
2Goetz MP, Knox SK, Suman V J, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen[J]. Breast Cancer Res Treat, 2007, 101(1): 113-121.
-
3Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamox- ifen biotransformation is associated with clinical outcomes of effi- cacy and hot flashes[J]. J Clin Oncol, 2005, 23(36): 9312-9318.
-
4Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CP2C19 genotypes[J]. J Clin Oncol, 2007, 25(33): 5187-5193.
-
5Bonanni B, Macis D, Maisonneuve P, Johansson HA. Polymor- phisms in the CYP2D6 tamoxifen metabolising gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial[J]. J Clin Oncol, 2006, 24(22): 3708-3709.
-
6Newman WG, Hadfield KD, Latif A, et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients[J]. Clin Cancer Res, 2008, 1408): 5913-5918.
-
7Nowell SA, Ahn J, Rae JIM, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and re-currence of disease in breast cancer patients[J]. Breast Cancer Re- search and Treatment, 2005, 91(3): 249-258.
-
8Wegman P, Vainikka L, Stal O, et al. Genotype of metabolic en- zymes and the benefit of tamoxifen in postmenopausal breast can- cer patients[J]. Breast Cancer Research. 2005, 7(3): 284-290.
-
9Wegman P, Elingarami S, Carstensen J, et al. Genetic variations of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen re- sponse in postmenopausal patients with breast cancer [J]. Breast Cancer Research. 2007, 9(1): 7.
-
10Abraham JE, Maranian MJ, Driver KE, et al. CYP2D6 gene vari- ants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen [J]. Breast Cancer Research, 2010, 12 (4): R64.
-
1王雅葳.联合使用不同种类肾素——血管紧张素系统药物被限制[J].药物不良反应杂志,2014,16(3):152-152.
-
2蒋彦章.西布曲明:建议在欧盟范围内暂停销售[J].药物流行病学杂志,2011,20(5):232-232.
-
3替比夫定与聚乙二醇干扰素联用致周围神经病变风险增加[J].药物不良反应杂志,2008,10(2):152-152. 被引量：2
-
4欧盟警告抗精神病药的静脉血栓栓塞风险[J].中国社区医师（医学专业）,2010(18):8-8.
-
5欧盟评估抗精神病药的静脉血栓栓塞风险[J].中国执业药师,2010(5):18-18.
-
6EC批准依度沙班用于高危的非瓣膜病房颤患者[J].临床合理用药杂志,2015,8(20):122-122.
-
7欧盟罗格列酮标签加强禁忌证的说明[J].国际药学研究杂志,2008,35(3):226-226.
-
8CHMP已加快对诺华心力衰竭治疗新药LCZ696的审批[J].临床合理用药杂志,2015,8(2):111-111.
-
9何文俊,秦红霖.欧洲修订红细胞生成素类药物的药品说明书[J].国际药学研究杂志,2008,35(2):86-86.
-
10张海澄.吗丁啉会致恶性心律失常？[J].大众健康,2015,0(2):46-47.
